Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels
文献类型：期刊论文
| 作者 | Hu, Hai-ning1,2; Zhou, Ping-zheng3; Chen, Fei1,2; Li, Min3; Nan, Fa-jun1,2 ; Gao, Zhao-bing3
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2013-10 |
| 卷号 | 34期号:10页码:1359-1366 |
| 关键词 | KCNQ2 channel retigabine HN38 XE991 structure modification CHO cell whole-cell recording |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/aps.2013.79 |
| 文献子类 | Article |
| 英文摘要 | Aim: Retigabine, an activator of KCNQ2-5 channels, is currently used to treat partial-onset seizures. The aim of this study was to explore the possibility that structure modification of retigabine could lead to novel inhibitors of KCNQ2 channels, which were valuable tools for KCNQ channel studies. Methods: A series of retigabine derivatives was designed and synthesized. KCNQ2 channels were expressed in CHO cells. KCNQ2 currents were recorded using whole-cell voltage clamp technique. Test compound in extracellular solution was delivered to the recorded cell using an ALA 8 Channel Solution Exchange System. Results: A total of 23 retigabine derivatives (HN31-HN410) were synthesized and tested electrophysiologically. Among the compounds, HN38 was the most potent inhibitor of KCNQ2 channels (its IC50 value=0.10 +/- 0.05 mu mol/L), and was 7-fold more potent than the classical KCNQ inhibitor XE991. Further analysis revealed that HN38 (3 mu mol/L) had no detectable effect on channel activation, but accelerated deactivation at hyperpolarizing voltages. In contrast, XE991 (3 mu mol/L) did not affect the kinetics of channel activation and deactivation. Conclusion: The retigabine derivative HN38 is a potent KCNQ2 inhibitor, which differs from XE991 in its influence on the channel kinetics. Our study provides a new strategy for the design and development of potent KCNQ2 channel inhibitors. |
| WOS关键词 | LINOPIRDINE |
| 资助项目 | National Science and Technology Major Project on "Key New Drug Creation and Manufacturing Program"[2013ZX09103001-016] ; National Key Basic Research Program of China[2013CB910604] ; National Natural Science Foundation of China for Excellent Key Laboratory[81123004] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000325276400012 |
| 出版者 | ACTA PHARMACOLOGICA SINICA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/277444]  |
| 专题 | 国家新药筛选中心 中科院受体结构与功能重点实验室 新药研究国家重点实验室 神经药理学研究国际科学家工作站 |
| 通讯作者 | Nan, Fa-jun |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hu, Hai-ning,Zhou, Ping-zheng,Chen, Fei,et al. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels[J]. ACTA PHARMACOLOGICA SINICA,2013,34(10):1359-1366. |
| APA | Hu, Hai-ning,Zhou, Ping-zheng,Chen, Fei,Li, Min,Nan, Fa-jun,&Gao, Zhao-bing.(2013).Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.ACTA PHARMACOLOGICA SINICA,34(10),1359-1366. |
| MLA | Hu, Hai-ning,et al."Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels".ACTA PHARMACOLOGICA SINICA 34.10(2013):1359-1366. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。